Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUGOGO Study C: Intravenous methylprednisolone dose comparison in moderately severe Graves' ophthalmopathy
NL-OMON20884Recruiting
- Sponsor
- Prof. dr. W.M. Wiersinga Dept. of Endocrinology and Metabolism Academic Medical Center Meibergdreef 9 1105 AZ Amsterdam T: +31 20 566 6071 F: +31 20 691 7682 e-mail: [email protected]
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methylprednisolone in Graves' ophthalmopathy (TED) (3 arms), sponsored by Prof. dr. W.M. Wiersinga Dept. of Endocrinology and Metabolism Academic Medical Center Meibergdreef 9 1105 AZ Amsterdam T: +31 20 566 6071 F: +31 20 691 7682 e-mail: [email protected]. Primary endpoints: Efficacy response and Safety score. Started Sep 2005; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NL-OMON20884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20884.